Agios Pharma & Eleven Biotherepeutics driven by sentiments

AGIO – Agios Pharmaceuticals, Inc is a biopharmaceutical company, engaged in the discovery and development of medicines for the treatment of cancer and genetic disorders.

AGIO – Agios Pharmaceuticals, Inc

Fundamentals Previously closed at 50.35
Day’s high 55.96
Day’s low 50.02
P/E ratio NA
EPS -3.62


Analysts opinion Agios Pharma announced positive results for its phase 1 Drug AG-348, used to treat anaemia. The stock was upgraded by Canaccord Genuity and J. P Morgan to “Buy”. Analyst confidence meter, a proprietary algorithm of Stockal gives 66% buy based on analyst ratings.
Sentiments AGIO fell, after having gained 8% Pre-Market today. The sentiment index is 100% negative according to Stockal proprietary algorithm.
Social Media Pulse The stock has 10% lower social media chatter than usual.

Continue Reading…

EBIO and XTLY may have bullish sentiments

EBIO – Eleven Biotherapeutics, Inc, a clinical-stage biotech company, hit the bottom after announcing that its investigational eye drop failed as a cure for allergic conjunctivitis.

EBIO – Eleven Biotherepeutics, Inc
Fundamentals Previously closed at 0.31
Day’s high 0.31
Day’s low 0.27
P/E ratio NA
EPS -1.71


Analyst opinion The recent stock sell-off’s seem to have hit the biotech company really hard, with EBIO hitting a new low, losing more than 90% in value as compared to last year. The failed- experimental eye-drop “isunakinra”, being the biggest reason for the price drop. However, just a week ago, the market cap of EBIO was as low as $5.3 million, which is way low compared to its cash balance reported at the end of Q3 last year which amounts to $46 million
Sentiments Though EPS is negative, we can see that the EPS has improved compared to prior year. EBIO has good fundamentals with a P/S ratio of 7.04, a P/B ratio of 0.20, a P/C ratio of 0.12 and a Quick ratio of 6.20.
91% analysts have a buy opinion for the stock.
Social pulse The social media pulse is 35% lower than normal.

Continue Reading…